Bacterial Conjunctivitis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Bacterial Conjunctivitis - Pipeline Review, H2 2018’, provides an overview of the Bacterial Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis

- The report reviews pipeline therapeutics for Bacterial Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Bacterial Conjunctivitis therapeutics and enlists all their major and minor projects

- The report assesses Bacterial Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bacterial Conjunctivitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bacterial Conjunctivitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

InSite Vision Inc

Laboratorios Sophia SA de CV

Shire Plc

InSite Vision Inc

Laboratorios Sophia SA de CV

Shire Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacterial Conjunctivitis – Overview

Bacterial Conjunctivitis – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacterial Conjunctivitis – Overview

Bacterial Conjunctivitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bacterial Conjunctivitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacterial Conjunctivitis – Companies Involved in Therapeutics Development

InSite Vision Inc

Laboratorios Sophia SA de CV

Shire Plc

Bacterial Conjunctivitis – Drug Profiles

azithromycin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Target Alpha-Hemolysin for Bacterial Infections – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISV-405 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levofloxacin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazufloxacin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-640 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vancomycin hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacterial Conjunctivitis – Dormant Projects

Bacterial Conjunctivitis – Product Development Milestones

Featured News & Press Releases

Jun 17, 2015: Manhattan U.S. Attorney Settles Civil Fraud Claims Against Inspire Pharmaceuticals For Its Misleading Marketing Designed To Cause Prescriptions Of Azasite For Non-Fda Approved Uses

Mar 17, 2015: InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical

Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US

Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops

Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops

Jun 17, 2013: InSite Vision Announces Joint Patent Infringement Lawsuit With Merck Against Mylan Pharma

Mar 26, 2013: InSite Vision Wins Appeal Of Patent Interference Litigation Against University Of California, San Francisco

Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision

Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bacterial Conjunctivitis, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development ...

List of Tables

Number of Products under Development for Bacterial Conjunctivitis, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Bacterial Conjunctivitis – Pipeline by InSite Vision Inc, H2 2018

Bacterial Conjunctivitis – Pipeline by Laboratorios Sophia SA de CV, H2 2018

Bacterial Conjunctivitis – Pipeline by Shire Plc, H2 2018

Bacterial Conjunctivitis – Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Bacterial Conjunctivitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Bacterial Conjunctivitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports